TCL Archive Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone April 10, 1987
TCL Archive Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment February 7, 2014
TCL Archive NCI’s Independence To Be Challenged By Edwards When Cancer Act Comes Up For Renewal Next Year December 21, 1973